People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Other Health Care, Other, Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| LumiraDx Ltd | — | Other Health Care | Series D+ | $779.1M | $3.5B | 2016 |
| Alere Inc. | — | Other Health Care | Series D+ | $500.0M | $9.2B | 2009 |
| Scvngr, Inc. | — | Other | Series B | $73.2M | $8.3M | 2016 |
| Endolytix Technology, Inc. | — | Pharmaceuticals | Series A | $21.3M | $25.0M | 2021 |
| ElectraDx, Inc. | — | Other Health Care | Series A | $14.8M | $80.7M | 2024 |
| Immunetics, Inc. | — | Biotechnology | Pre-Seed | $1.5M | $46.1M | 2012 |
RON ZWANZIGER at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside RON ZWANZIGER on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Scott | 3 | 12 |
| David Walton | 2 | 3 |
| Peter Scheu | 2 | 2 |
| John Yonkin | 2 | 2 |
| Jerry McAleer | 2 | 2 |
| ANDREW LEVIN | 1 | 17 |
| Gerald Chan | 1 | 13 |
| Peter Bell | 1 | 11 |
| John Levy | 1 | 10 |
| Rich Miner | 1 | 9 |
| Gary Magnant | 1 | 5 |
| BRIAN CARROLL | 1 | 5 |
| John Peterson | 1 | 4 |
| John Patterson | 1 | 4 |
| Brian Mitchell | 1 | 4 |
| John Quelch | 1 | 4 |
| Donald Berwick | 1 | 3 |
| PHILIP BUCHANAN | 1 | 3 |
| George Neble | 1 | 3 |
| RON GERATY | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.